BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) – Pipeline Insight, 2020
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Non-Small Cell Lung Cancer (NSCLC): Overview
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.
The three main histological subtypes of Non-Small Cell Lung Cancer are:
BRAF mutations
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy, but responses to tyrosine kinase inhibitors such as BRAF inhibitors with or without MEK inhibitors have provided another effective tool to attain better response rates when compared to cytotoxic chemotherapy. New strategies such as immunotherapy are becoming as well another option to treat in the second-line setting patients with BRAF-mutated NSCLC.
Molecular pathways
BRAF gene encodes a serine/threonine-protein kinase that regulates normal cell growth and proliferation. The amino acid residues that specifically encode the kinase domain of BRAF are 457–717. The activation loop of the kinase is located within the residues 596–600, which interact with the phosphate-binding loop keeping the kinase locked. Once the activation loop is phosphorylated, BRAF can also phosphorylate and thus activate the mitogen-activated 2 kinase 1 and 2 (MAP2K 1/2) signaling pathway (also known as MEK1/2), which will phosphorylate the tyrosine and threonine residues of the MAPK ERK1/2 proteins. ERK1/2 will activate by phosphorylation proteins of the MAPKAPKK family and cytoskeletal proteins such as vimentin and keratin-8. ERK 1 and 2 will also translocate to the nucleus activating transcription factors such as FOS, TP53, and ELK1.
Immunotherapy in patients with BRAF mutations
Targeting BRAF V600E mutations with a combination of BRAF and MEK inhibitors appear to be the best frontline option for patients with this oncogenic driver. There are insufficient data to determine the responses for patients with BRAF non-V600E mutations. According to phase II trials, the responses to combined BRAF/MEK inhibitors in the first-line setting is higher than if given in the second line or beyond. BRAF V600E appears to confer aggressive biology, and cytotoxic chemotherapy is inferior when used in the first-line setting. The second-line treatment is unclear at this moment. Immune checkpoint inhibitors appear to have some activity in retrospective analyses, but further prospective trials are needed to establish their efficacy in this subset of patients.
BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the BRAF-mutant Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs
Further product details are provided in the report……..
BRAF-mutant Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different BRAF-mutant Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
BRAF-mutant Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BRAF-mutant Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BRAF-mutant Non-Small Cell Lung Cancer drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Non-Small Cell Lung Cancer (NSCLC): Overview
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.
The three main histological subtypes of Non-Small Cell Lung Cancer are:
- Adenocarcinoma: About 40% of all lung cancers are adenocarcinomas. These tumors start in mucus-producing cells that line the airways.
- Squamous cell carcinoma (SCC): About 25-30% of all lung cancers are Squamous cell carcinoma. This type of cancer develops in cells that line the airways and is usually caused by smoking.
- Large cell (undifferentiated) carcinoma: This type makes up around 10-15% of all lung cancers. It gets its name from the way that the cancer cells look when they are examined under a microscope.
BRAF mutations
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy, but responses to tyrosine kinase inhibitors such as BRAF inhibitors with or without MEK inhibitors have provided another effective tool to attain better response rates when compared to cytotoxic chemotherapy. New strategies such as immunotherapy are becoming as well another option to treat in the second-line setting patients with BRAF-mutated NSCLC.
Molecular pathways
BRAF gene encodes a serine/threonine-protein kinase that regulates normal cell growth and proliferation. The amino acid residues that specifically encode the kinase domain of BRAF are 457–717. The activation loop of the kinase is located within the residues 596–600, which interact with the phosphate-binding loop keeping the kinase locked. Once the activation loop is phosphorylated, BRAF can also phosphorylate and thus activate the mitogen-activated 2 kinase 1 and 2 (MAP2K 1/2) signaling pathway (also known as MEK1/2), which will phosphorylate the tyrosine and threonine residues of the MAPK ERK1/2 proteins. ERK1/2 will activate by phosphorylation proteins of the MAPKAPKK family and cytoskeletal proteins such as vimentin and keratin-8. ERK 1 and 2 will also translocate to the nucleus activating transcription factors such as FOS, TP53, and ELK1.
Immunotherapy in patients with BRAF mutations
Targeting BRAF V600E mutations with a combination of BRAF and MEK inhibitors appear to be the best frontline option for patients with this oncogenic driver. There are insufficient data to determine the responses for patients with BRAF non-V600E mutations. According to phase II trials, the responses to combined BRAF/MEK inhibitors in the first-line setting is higher than if given in the second line or beyond. BRAF V600E appears to confer aggressive biology, and cytotoxic chemotherapy is inferior when used in the first-line setting. The second-line treatment is unclear at this moment. Immune checkpoint inhibitors appear to have some activity in retrospective analyses, but further prospective trials are needed to establish their efficacy in this subset of patients.
BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the BRAF-mutant Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs
- Vemurafenib: Roche
Further product details are provided in the report……..
BRAF-mutant Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different BRAF-mutant Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in BRAF-mutant Non-Small Cell Lung Cancer
Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intramuscular
- Oral
- Intratumoral
- Intravenous
- Molecule Type
- Gene therapies
- Bispecific antibodies
- Immunotherapies
- Monoclonal antibodies
- Small molecules
- Product Type
BRAF-mutant Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BRAF-mutant Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BRAF-mutant Non-Small Cell Lung Cancer drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence BRAF-mutant Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve BRAF-mutant Non-Small Cell Lung Cancer.
- BRAF-mutant Non-Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing BRAF-mutant Non-Small Cell Lung Cancer drugs?
- How many BRAF-mutant Non-Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of BRAF-mutant Non-Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the BRAF-mutant Non-Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for BRAF-mutant Non-Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Roche
- Array BioPharma/Ono Pharmaceutical
- Jazz Pharmaceuticals/Redx Pharma
- Merck
- AstraZeneca
- Novartis Oncology
- Vemurafenib
- Research programme: pan-RAF inhibitors
- MK 2206
Introduction
Executive Summary
BRAF-mutant Non-Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
BRAF-mutant Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
BRAF-mutant Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
BRAF-mutant Non-Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Vemurafenib: Roche
Product Description
Research and Development
Product Development Activities
Encorafenib: Array BioPharma/Ono Pharmaceutical
Product Description
Research and Development
Product Development Activities
MK 2206: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: pan-RAF inhibitors: Jazz Pharmaceuticals/Redx Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
BRAF-mutant Non-Small Cell Lung Cancer Key Companies
BRAF-mutant Non-Small Cell Lung Cancer Key Products
BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
BRAF-mutant Non-Small Cell Lung Cancer Key Companies
Appendix
Executive Summary
BRAF-mutant Non-Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
BRAF-mutant Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
BRAF-mutant Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
BRAF-mutant Non-Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Vemurafenib: Roche
Product Description
Research and Development
Product Development Activities
Encorafenib: Array BioPharma/Ono Pharmaceutical
Product Description
Research and Development
Product Development Activities
MK 2206: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: pan-RAF inhibitors: Jazz Pharmaceuticals/Redx Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
BRAF-mutant Non-Small Cell Lung Cancer Key Companies
BRAF-mutant Non-Small Cell Lung Cancer Key Products
BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
BRAF-mutant Non-Small Cell Lung Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for BRAF-mutant Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for BRAF-mutant Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for BRAF-mutant Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for BRAF-mutant Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
